Suppr超能文献

主要的 GDAP1 突变导致主要为轻度 CMT 表型。

Dominant GDAP1 mutations cause predominantly mild CMT phenotypes.

机构信息

VIB Department of Molecular Genetics, University of Antwerp, Antwerpen, Belgium.

出版信息

Neurology. 2011 Aug 9;77(6):540-8. doi: 10.1212/WNL.0b013e318228fc70. Epub 2011 Jul 13.

Abstract

OBJECTIVE

Ganglioside-induced differentiation associated-protein 1 (GDAP1) mutations are commonly associated with autosomal recessive Charcot-Marie-Tooth (ARCMT) neuropathy; however, in rare instances, they also lead to autosomal dominant Charcot-Marie-Tooth (ADCMT). We aimed to investigate the frequency of disease-causing heterozygous GDAP1 mutations in ADCMT and their associated phenotype.

METHODS

We performed mutation analysis in a large cohort of ADCMT patients by means of bidirectional sequencing of coding regions and exon-intron boundaries of GDAP1. Intragenic GDAP1 deletions were excluded using an allele quantification assay. We confirmed the pathogenic character of one sequence variant by in vitro experiments assaying mitochondrial morphology and function.

RESULTS

In 8 Charcot-Marie-Tooth disease (CMT) families we identified 4 pathogenic heterozygous GDAP1 mutations, 3 of which are novel. Three of the mutations displayed reduced disease penetrance. Disease onset in the affected individuals was variable, ranging from early childhood to adulthood. Disease progression was slow in most patients and overall severity milder than typically seen in autosomal recessive GDAP1 mutations. Electrophysiologic changes are heterogeneous but compatible with axonal neuropathy in the majority of patients.

CONCLUSIONS

With this study, we broaden the phenotypic and genetic spectrum of autosomal dominant GDAP1-associated neuropathies. We show that patients with dominant GDAP1 mutations may display clear axonal CMT, but may also have only minimal clinical and electrophysiologic abnormalities. We demonstrate that cell-based functional assays can be reliably used to test the pathogenicity of unknown variants. We discuss the implications of phenotypic variability and the reduced penetrance of autosomal dominant GDAP1 mutations for CMT diagnostic testing and counseling.

摘要

目的

神经节苷脂诱导分化相关蛋白 1(GDAP1)突变通常与常染色体隐性遗传性腓骨肌萎缩症(ARCMT)相关;然而,在极少数情况下,它们也会导致常染色体显性遗传性腓骨肌萎缩症(ADCMT)。我们旨在研究 ADCMT 中致病杂合 GDAP1 突变的频率及其相关表型。

方法

我们通过双向测序 GDAP1 的编码区域和外显子-内含子边界,对一大组 ADCMT 患者进行了突变分析。使用等位基因定量检测排除了内含子 GDAP1 缺失。我们通过体外实验检测线粒体形态和功能,证实了一个序列变异的致病性特征。

结果

在 8 个遗传性运动感觉神经病(CMT)家系中,我们鉴定出 4 个致病性杂合 GDAP1 突变,其中 3 个是新的。这 3 个突变的疾病外显率降低。受影响个体的发病时间不同,从儿童早期到成年期不等。大多数患者的疾病进展缓慢,总体严重程度低于常染色体隐性 GDAP1 突变。电生理变化具有异质性,但在大多数患者中与轴索性神经病相符。

结论

通过本研究,我们拓宽了常染色体显性 GDAP1 相关神经病的表型和遗传谱。我们表明,具有显性 GDAP1 突变的患者可能表现出明显的轴索性 CMT,但也可能只有轻微的临床和电生理异常。我们证明,基于细胞的功能检测可以可靠地用于测试未知变异的致病性。我们讨论了表型变异性和常染色体显性 GDAP1 突变的低外显率对 CMT 诊断检测和咨询的影响。

相似文献

1
Dominant GDAP1 mutations cause predominantly mild CMT phenotypes.主要的 GDAP1 突变导致主要为轻度 CMT 表型。
Neurology. 2011 Aug 9;77(6):540-8. doi: 10.1212/WNL.0b013e318228fc70. Epub 2011 Jul 13.

引用本文的文献

1
Update on recent advances in amyotrophic lateral sclerosis.肌萎缩侧索硬化症的最新进展综述。
J Neurol. 2024 Jul;271(7):4693-4723. doi: 10.1007/s00415-024-12435-9. Epub 2024 May 27.
2
Genetic etiology of progressive pediatric neurological disorders.进行性儿科神经障碍的遗传病因学。
Pediatr Res. 2024 Jan;95(1):102-111. doi: 10.1038/s41390-023-02767-z. Epub 2023 Aug 10.
3
Understanding foot conditions, morphologies and functions in children: a current review.了解儿童足部状况、形态和功能:当前综述
Front Bioeng Biotechnol. 2023 Jul 19;11:1192524. doi: 10.3389/fbioe.2023.1192524. eCollection 2023.

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验